Initially identified as a proto-oncogene amplified in neuroblastoma, MYCN amplification occurs in 20%-30% of neuroblastoma cases, serving as a critical prognostic marker associated with poorer outcomes (4). This evidence concerns the gene MYCN and neuroblastoma.